Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
Globe Newswire•05/10/2026•07:32 ET
5
Key Highlights
- ➤Polyrizon (PLRZ) filed U.S. divisional patent application No. 19/823,285
- ➤Application covers mucoadhesive polymers for nasal drug delivery
- ➤Filing expands protection for Polyrizon’s existing mucoadhesive patent family
- ➤Technology targets local or systemic therapeutic delivery through nasal mucosa
Expert Statements
Tomer Izraeli, Chief Executive Officer of Polyrizon
“This new U.S. patent filing represents another step in strengthening the intellectual property foundation supporting our intranasal technology platform. We believe our mucoadhesive technology has potential beyond stand-alone barrier applications, particularly as a platform for delivering therapeutic agents through the nasal mucosa. Pursuing additional patent protection for these applications is an important part of our strategy as we continue to explore the broader potential of our technology.”
A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery.
Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced that it has filed a new U.S. divisional patent application with the United States Patent and Trademark Office (USPTO), further expanding the Company’s intellectual property portfolio relating to its proprietary mucoadhesive technology.
Get started
Create a free account to read the full story.